AlloSource has launched AceConnex Pre-Sutured Fascia, a fascia allograft device for hip labral reconstruction and augmentation.

The device, which received 510(k) approval from the US Food and Drug Administration (FDA), has already been used across the US during its limited launch phase.

Designed to ensure consistency and reduced variability in surgical procedures, the AceConnex Pre-Sutured Fascia remains tightly bound. This offers an advantage over allografts that are sutured in the operating room.

The device is intended to be used as a component in soft tissue surgical procedures, specifically for the reconstruction or augmentation of the labrum.

The ready-to-use device eliminates the time surgeons would typically spend suturing during complex reconstruction procedures.

Additionally, it comes in 5.0mm-5.4mm and 5.5mm-6.0mm diameters, providing further options for patient-specific treatment.

Each length of the AceConnex Pre-Sutured Fascia can be customised to fit the specific requirements of the surgeon and patient.

AceConnex Pre-Sutured Fascia is available in three trimmable lengths to accommodate different surgical needs, including segmental and circumferential labral reconstruction.

AlloSource president and CEO Dean Elliott said: "AceConnex Pre-Sutured Fascia demonstrates AlloSource’s commitment to providing innovative products to support surgeons, in this case specifically hip arthroscopists.

"With the positive feedback from surgeons who have used the product, we are excited to get it in the hands of more medical professionals, as we embark on this full launch."

The ready-to-use sterile device is said to saves 24 to 45 minutes time.

It retains functionality at a shelf-life of two years and is also verified with in-process length and diameter measurements.